Visite o curriculum vitae completo do autor clicando aqui

Formação Acadêmica

  • Doutorado (PhD) – Institut Jules Bordet & École de Santé Publique – Université Libre de Bruxelles, Bruxelas, Bélgica; 2011 – 2014.
  • Curso de Desenvolvimento de Pesquisa Médica em Oncologia – Flims Workshop in Clinical Research, Flims, Suiça; 2011.
  • Mestrado – Institut Gustave Roussy & Université Paris XI, Paris, França; 2009 – 2011.
  • Residência em Oncologia Clínica – Instituto Nacional de Cancer / INCA, Rio de Janeiro, Brasil; 2007 – 2009.
  • Residência em Medicina Interna – Hospital Central do Exercito / HCE, Rio de Janeiro, Brasil; 2004 – 2006.
  • Graduação em Medicina – Universidade Federal do Rio de Janeiro / UFRJ, Rio de Janeiro, Brasil, 1998 – 2003.

Publicações

  1. Distúrbios hidroeletrolítico, ácido-básicos e metabólicos no pós operatório complicado Complicações Cirúrgicas – Prevenção e Tratamento.1a Edição: Editora Guanabara Koogan 2005.
  2. Nutrição enteral e parenteral nas complicações cirúrgicas. Complicações Cirúrgicas – Prevenção e Tratamento.1a Edição: Editora Guanabara Koogan 2005.
  3. Síndrome de Envenenamento por 2.000 Picadas de Abelhas Africanizadas. RBTI – Revista Brasileira de Terapia Intensiva, Vol. 18 número 1. Janeiro 2006.
  4. Fator de inibição da migração de macrófagos e interleucina-6 na síndrome de esmagamento: analogia com gravidade? Relato de casos. Revista Brasileira de Terapia Intensiva, v. 19, p. 499-503, 2007. 2007.
  5. Profilaxia de recidiva de doença no sistema nervoso central de linfoma não Hodgkin difuso de grandes células B – Revisão sistemática da literatura, 2009.
  6. Avaliação Retrospectiva de Fatores Clínico- Patológicos das Pacientes com Câncer de Mama e Infiltração para Medula Óssea no Instituto Nacional de Câncer – INCA – Rio de Janeiro – RJ. Brazilian Oncology National Congress, 2009.
  7. Cutaneous Malignant Melanoma: Clinical and biological diversity, a first step toward personalised therapy. DUERCC Conclusion Thesis, 2010.
  8. Benefit-Risk Assessment of Bevacizumab in the Treatment of Breast Cancer. Adisonline.com Drug Safety, December 1, 2011.
  9. Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma. Dermatol Res Pract. 2012;2012:259170. Epub 2011 Dec 15.
  10. Targeted treatments of HER2-positive metastatic breast cancer: trastuzumab and beyond. Breast Cancer Management, September 2012.
  11. Multidisciplinary Management of Complex Cases. Oxford Textbook of Oncology (OTO), Third Edition.
  12. Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumor origin in Cancer of Unknown Primary (CUP). Maney Publishing, Journal of Chemotherapy, March 2013.
  13. Clinical Research in HER2 Positive Metastatic Breast Cancer – Ethical Issues of Trials Conducted in Low Resource Environments, ESMO, May 6, 2013.
  14. Trastuzumab for patients with HER2 positive breast cancer: Delivery, duration and combination therapies. The Breast, August 1, 2013.
  15. Discrepancies in cancer incidence and mortality and its relationship to health expenditure in the 27 European Union member states, Annals of Oncology, October 2013.
  16. Lapatinib Versus Placebo Added to Paclitaxel in First-Line Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Ethical Lessons Not Learned From Africa. Journal of Clinical Oncology, October 14, 2013.
  17. Clinical practice-changing trials: the HERA study paradigm. Expert Rev Anticancer Ther, October 2013.
  18. Surgical Management of Primary Tumor in Newly Diagnosed Metastatic Breast Cancer Patients. A Systematic Review of the Literature. ABC2 P042 – Second Consensus Conference for Advanced Breast Cancer, 2013.
  19. Controversial Issues in Early Stage Breast Cancer: a Global Collaborative Survey, supported by the European Society for Medical Oncology (ESMO). Annals of Oncology, February 22, 2014.
  20. Oncoquiz – What is your diagnosis? Belgian Journal of Medical Oncology (Belg J Med Oncol 2014;8(1):21-2), March 2014.
  21. Anticancer drug development: moving away from the old habits. Curr Opin Oncol. 2014 Mar 7. March 7, 2014.
  22. An Exploratory Analysis of the Factors Leading to Delays in Cancer Drug Reimbursement in the European Union: The Trastuzumab Case. European Breast Cancer Conference EBCC2014 – Abstract 125, March 2014.
  23. Cardiotoxicity of systemic agents used in breast cancer. The Breast, May 1, 2014.
  24. Current multidisciplinary management in breast cancer. European Journal of Cancer, March 2014.
  25. A comparative analysis of the association between health expenditure and cancer survival in 168 countries. 2014 ASCO Annual Meeting, June 1, 2014.
  26. Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives. Journal of Clinical Oncology, July 21, 2014.
  27. Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA. ESMO Congress 2014 – Madrid, September 27, 2014.
  28. An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: The trastuzumab case. European Journal of Cancer, October 19, 2014.
  29. Hurdles and delays in access to anti-cancer drugs in Europe. ecancer medical science, November 2014.

Membro de Organizações Científicas e Sociedades Médicas

  • Flims Alumni Club – Membro Ativo.
  • APHINITY – Joint Study Monitory Team – Membro do Science Team. Outubro de 2011 – junho de 2014.
  • European Society for Medical Oncology – Membro Ativo.
  • Comite de Jovens Oncologistas da Sociedade Brasileira de Oncologia Clinica – Membro Ativo.
  • Sociedade Brasileira de Oncologia Clinica – Membro Ativo.
  • Revista Médica Ecancer Medical Science – Membro do Corpo Editorial.
  • LACOG – Latin American Cooperative Oncology Group – Membro Ativo.